Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate
Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e1350-e1359
DOI: 10.1093/cid/ciac418 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 26.05.2022. Verfasst von Sanjay S Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Pharmaceuticals International AG, Zurich, Switzerland. Hauptthemen laut MEDLINE: Dengue, Dengue Vaccines. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
An unmet medical need remains for an effective dengue tetravalent vaccine that can be administered irrespective of previous dengue exposure. TAK-003, a dengue tetravalent vaccine, has demonstrated efficacy in an ongoing phase 3 trial in children and adolescents living in dengue-endemic areas, with an acceptable safety profile in both dengue-naive and dengue-exposed individuals.
Methods
Safety findings are presented herein from an integrated analysis of data for healthy 4–60-year-olds from two phase 2 and three phase 3 double-blind, placebo-controlled clinical trials of TAK-003 (TAK-003, n = 14 627; placebo, n = 7167). Safety evaluation included analyses of postinjection reactogenicity, unsolicited adverse events (AEs), serious AEs (SAEs), and deaths. Subgroup analyses were performed by age group, baseline serostatus, and gender.
Results
The most common local and systemic AEs were injection site pain (43% for TAK-003 and 26% for placebo) and headache (34% and 30%, respectively). Injection site AEs were mostly mild and resolved within 1–3 days. Unsolicited AEs and AEs leading to discontinuation occurred with similar frequency across both groups, while SAEs were fewer for TAK-003 recipients (6% vs 8% for placebo). Four of the 5 vaccine-related SAEs (which included hypersensitivity, dengue fever, and dengue hemorrhagic fever) occurred in the placebo group. No deaths were considered vaccine-related. Subgroup analyses showed no differences in safety by baseline serostatus or by gender, albeit analysis by age indicated greater local reactogenicity rates for adolescents (46% for TAK-003 and 28% for placebo) and adults (56% and 19%, respectively) than for children (37% and 25%, respectively).
Conclusions
No important safety risks were identified, and TAK-003 was well tolerated irrespective of age, gender, or baseline dengue serostatus in recipients aged 4–60 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Takeda Pharmaceuticals International AG, Zurich, Switzerland.
- Takeda Pharmaceuticals International Inc, Cambridge, Massachusetts, USA.
Zitieren
APA
Patel, S. S., Rauscher, M., Kudela, M., & Pang, H. (2023). Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate. Clinical Infectious Diseases, 76(3), e1350-e1359. https://doi.org/10.1093/cid/ciac418
Vancouver
Patel SS, Rauscher M, Kudela M, Pang H. Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate. Clinical Infectious Diseases. 2023;76(3):e1350-e1359. doi:10.1093/cid/ciac418
BibTeX
@article{Patel2023,
author = {Patel, Sanjay S and Rauscher, Martina and Kudela, Maria and Pang, Hang},
title = {Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {3},
pages = {e1350--e1359},
doi = {10.1093/cid/ciac418}
}
EUVIMED